Sure.... The extra operations we've just been approved for in the EU as a total far outnumber the operations we were previously approved for. Our prospective market has just become many many times larger.
Surgeons in the EU have been keenly awaiting this development whilst the EU regulators have been dragging their heels so now that they permission to use CardioCel for a far greater number and variety of surgical procedures we will see sales increase significantly.
Ann: Admedus achieves label expansion for CardioCel in Europe, page-10
-
- There are more pages in this discussion • 156 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.22 |
Change
0.740(6.45%) |
Mkt cap ! $258.3M | |||
| Open | High | Low | Value | Volume |
| $11.50 | $12.25 | $11.49 | $395.2K | 33.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $11.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.22 | 127 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |